GlassScriptPhysician profile
Mark A Jung
NPI 1528356565
$2,966.14
in general payments reported to CMS, 2019-2025
32 companies · $855 in 2025
The $855 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.48 · 2020: $25.75 · 2021: $329 · 2022: $299 · 2023: $515 · 2024: $899 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.28 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $447.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $446.25 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $166.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $119.34 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $114.82 | 2022 | |
| Pfizer INC. | $113.75 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $99.34 | 2023-2025 | Livalo, Seglentis, Zoryve |
| Sanofi Pasteur INC. | $93.05 | 2022-2024 | |
| Novo Nordisk INC | $89.64 | 2025 | Wegovy |
| Halozyme INC | $79.37 | 2023 | |
| Fidia Pharma USA INC. | $77.47 | 2019-2021 | |
| Antares Pharma, INC. | $64.65 | 2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $50.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.73 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.30 | 2023-2024 | Spiriva Respimat, Ofev |
| Sumitomo Pharma America, INC. | $44.07 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $43.61 | 2021 | |
| Amgen INC. | $41.15 | 2025 | Repatha, Otezla |
| Corium, LLC | $40.31 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $39.46 | 2024-2025 | Capvaxive, Gardasil 9, Vaqta |
| Ferring Pharmaceuticals INC. | $32.00 | 2025 | Euflexxa |
| Globus Medical, INC. | $29.11 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.79 | 2023 | Xifaxan |
| Tris Pharma INC | $20.01 | 2024 | Dyanavel Xr |
| Depuy Synthes Sales INC. | $18.74 | 2019 | |
| Currax Pharmaceuticals LLC | $17.53 | 2025 | Contrave |
| Tolmar, INC. | $16.35 | 2025 | Jatenzo |
| Ibsa Pharma INC. | $15.75 | 2024 | Licart, Tirosint |
| Greer Laboratories, INC. | $14.63 | 2023 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $14.40 | 2025 | Neffy |
| Endo Pharmaceuticals INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.